Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | SABS SAB Biotherapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $3.17 -1.6% | $16.31 +6.3% |
| StockIQ Score | 42D Weak Risk: High | 42D Weak Risk: Medium |
| Technical | 9F | 36F |
| Fundamental | 54C- | 35F |
| Growth | 54C- | 50C- |
| Fair Value | 38F | 38F |
| News | 92A+ | 50C- |
| Quality | 42D | 50C- |
| Risk | 40D | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Both SABS and AAPG have an investor score of 42, a valuation score of 38, and each carries a WEAK rating. SABS outperforms AAPG in fundamental (54 vs 35) and growth (54 vs 50) scores. AAPG has a higher technical score (36 versus 9).
